LEO Science & Tech Hub announce new collaboration to develop technology for minimally-invasive dermal biomarker assessment
LEO Science & Tech Hub today announced a two-year collaboration with the Karp Lab at Brigham and Women’s Hospital (BWH) to develop minimally-invasive technology to advance dermal biomarker assessment.
The Karp Lab, led by Jeffrey Karp, PhD, at BWH focuses on the development of platform technology and translational research to improve patient care. LEO Science & Tech Hub is an R&D innovation unit of LEO Pharma dedicated to identifying, developing, and funding innovative solutions that improve the lives of people with skin diseases.
LEO Science & Tech Hub and the Karp Lab will explore and develop technologies that could enable frequent and minimally-invasive assessment of relevant dermal biomarkers during clinical studies as well as the potential for diagnostic use in point-of-care testing. This kind of assessment could limit the number of painful skin biopsies patients must endure, and provide physicians with immediate feedback on how well a drug regimen is working.
Read more here.